Literature DB >> 10320860

Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.

T van der Weijden1, J A Knottnerus, A J Ament, H E Stoffers, R P Grol.   

Abstract

STUDY
OBJECTIVE: To investigate and evaluate published data on cost effectiveness of cholesterol lowering interventions, and how this information could be interpreted in a rational approach of cholesterol management in general practice.
DESIGN: A systematic review of the literature.
SETTING: No restriction on setting. MATERIALS: Papers reporting on the cost effectiveness or cost utility of prevention of (recurrent) coronary heart disease by reduction of hypercholesterolaemia in adults. MAIN
RESULTS: Thirty nine studies, most cost effectiveness analyses, were included. In 24 studies drug interventions only were analysed. Costs of screening to target cholesterol lowering interventions to persons with hypercholesterolaemia were considered in nine studies. Adjustments of the efficacy of the intervention for community effectiveness were described in seven studies. In four studies life years gained were adjusted for quality of life. Despite large variation in the outcomes, there is a constant tendency towards a less favourable cost effectiveness ratio for intervening in persons without coronary heart disease compared with persons with coronary heart disease and for women compared with men.
CONCLUSIONS: There is lack of data on cost effectiveness of cholesterol lowering interventions in the general practice setting. The cost effectiveness of cholesterol lowering in general practice deteriorates when all relevant costs are taken into account and when efficacy is corrected for community effectiveness. Cholesterol lowering intervention is more cost effective in men compared with women and in patients with coronary heart disease compared with persons without coronary heart disease. Considerations from cost effectiveness analyses should be incorporated into the development and implementation of national cholesterol guidelines for general practitioners. Standardisation of cost effectiveness studies is important for future economic evaluations.

Entities:  

Mesh:

Year:  1998        PMID: 10320860      PMCID: PMC1756760          DOI: 10.1136/jech.52.9.586

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  95 in total

1.  How serious are the adverse effects of screening?

Authors:  W Feldman
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

2.  Medical management and managing medical care: the dilemma of evaluating new technology.

Authors:  B S Bloom
Journal:  Am Heart J       Date:  1990-03       Impact factor: 4.749

Review 3.  Outcome assessment in cardiovascular cost-benefit studies.

Authors:  B O'Brien; J Rushby
Journal:  Am Heart J       Date:  1990-03       Impact factor: 4.749

Review 4.  The design of future cost-benefit studies.

Authors:  A Maynard
Journal:  Am Heart J       Date:  1990-03       Impact factor: 4.749

5.  Estimating costs in the economic evaluation of medical technologies.

Authors:  B R Luce; A Elixhauser
Journal:  Int J Technol Assess Health Care       Date:  1990       Impact factor: 2.188

Review 6.  Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol.

Authors:  W B Stason
Journal:  Am Heart J       Date:  1990-03       Impact factor: 4.749

7.  A mathematical representation of the expert panel's guidelines for high blood cholesterol case-finding and treatment.

Authors:  J L Weissfeld; L A Weissfeld; J J Holloway; A M Bernard
Journal:  Med Decis Making       Date:  1990 Apr-Jun       Impact factor: 2.583

Review 8.  A clinician's guide to cost-effectiveness analysis.

Authors:  A S Detsky; I G Naglie
Journal:  Ann Intern Med       Date:  1990-07-15       Impact factor: 25.391

Review 9.  Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.

Authors:  K A Schulman; B Kinosian; T A Jacobson; H Glick; M K Willian; H Koffer; J M Eisenberg
Journal:  JAMA       Date:  1990-12-19       Impact factor: 56.272

10.  Effectiveness and hazards of case finding for a high cholesterol concentration.

Authors:  S Kinlay; R F Heller
Journal:  BMJ       Date:  1990-06-16
View more
  6 in total

1.  Management of UTI in general practice: a cost effective analysis. A commentary to facilitate an understanding of economic evaluation.

Authors:  D Kernick
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

2.  Statins and the prevention of coronary heart disease: striking a balance that is desirable, affordable, and achievable.

Authors:  L D Ritchie
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

3.  The primary prevention of coronary heart disease with statins: practice headache or public health?

Authors:  P H Evans
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

4.  Evaluation of community-wide interventions: the ecologic case-referent study design.

Authors:  P A Wiegersma; A Hofman; G A Zielhuis
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

5.  Methodological reviews of economic evaluations in health care: what do they target?

Authors:  Maria-Florencia Hutter; Roberto Rodríguez-Ibeas; Fernando Antonanzas
Journal:  Eur J Health Econ       Date:  2013-08-24

6.  Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial.

Authors:  M G Franzosi; M Brunetti; R Marchioli; R M Marfisi; G Tognoni; F Valagussa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.